Vlad Coric, Biohaven CEO (Photo Credit: Andrew Venditti)
As Amylyx decision waits in the wings, Biohaven’s ALS drug sinks (again) in platform trial
The FDA’s decision on Amylyx’s ALS drug is set to come out sometime Thursday. In a space with few drugs, any approval would be a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
